Multiparticulates like pellets, beads, and minitabs offer versatile solutions to address diverse patient-centric needs across pediatrics, geriatrics, and special populations. By overcoming key challenges such as palatability, swallowability, dosing flexibility, pill burden, and dosing frequency, multiparticulate systems enable tailored drug delivery with improved compliance and therapeutic outcomes. This presentation will explore how taste masking, flexible formats, modified-release technologies, and combination designs collectively position multiparticulates as an innovative approach that combines convenience, flexibility, and patient-centric oral delivery.

Learning Objectives:

• • Identify five major patient-centric challenges addressed by multiparticulate formulations: taste masking, swallowability, dosing flexibility, pill burden, and dosing frequency.
• • Explain how multiparticulate platforms enable customized, age-appropriate, and easy-to-administer dosage forms.
• • Evaluate formulation and process strategies (e.g., coating, layering, encapsulation) that enhance palatability, modified release, and support combination therapies.
• • Review case studies demonstrating the utilization of multiparticulates in patient-centric therapies for pediatrics, geriatrics, and chronic disease management.

Lipid excipients offer significant in vivo performance benefits for oral drug delivery by improving solubility/bioavailability, enhancing absorption, and mitigating food effect. While lipids have found commercial success in soft gel capsules and liquid-filled hard capsules, there is growing interest in incorporating the benefits of lipid excipients into oral solid dosage forms, such as tablets.

This presentation will highlight emerging research and formulation strategies that expand the use of lipid excipients in oral tablet development.

Key topics will include:

• In vivo benefits of lipid excipients for solubility and permeability.
• Combining lipids with polymers to optimize oral tablet performance.
• Incorporating lipids into tablets via common processing techniques.
• Case studies showcasing lipid-enabled tablet formulations.

Precise storage conditions are critical to maintaining the quality and integrity of pharmaceutical products. Pharma storage must provide secure, cGMP-compliant solutions backed by advanced infrastructure, including redundant power and cooling systems, 24/7 monitoring, and multi-layered access control.

A full spectrum of storage environments—from ambient, refrigerated, and ICH stability to ultra-low and cryogenic—are needed to meet industry and custom requirements.

In this webinar, experts from Alcami will explore how integrated services such as materials management, logistics, and on-site support can ensure seamless handling from receipt to delivery, preserving product quality and meeting regulatory standards.

Attendees will gain insight on how to safeguard critical materials, mitigate risk, and navigate complex storage requirements with confidence across every stage of the development lifecycle.

Effective DNA clearance is essential in viral vector manufacturing to ensure product purity, regulatory compliance, and patient safety. As demand for AAV and LVV-based cell and gene therapies grows, biopharmaceuticals and CDMOs must adopt scalable, high-performing endonucleases. 

This study evaluated Roche’s EndoCleave endonuclease against commercial benchmarks using a transient transfection platform with suspension HEK293 cells. Two Proof-of-Concept studies assessed performance across key process parameters—enzyme concentration, incubation time, temperature, and salt conditions—representative of AAV and LVV production. 

EndoCleave consistently matched the performance of commercially available endonuclease in reducing host cell and plasmid DNA without impacting viral titers. Its activity remained robust under varying conditions, confirming suitability for both AAV and LVV workflows. 

These results suggest EndoCleave as a reliable, scalable solution for removing nucleic acid in GMP-ready vector manufacturing environments and could also be a potential cost-effective solution.

Multiparticulates like pellets, beads, and minitabs offer versatile solutions to address diverse patient-centric needs across pediatrics, geriatrics, and special populations. By overcoming key challenges such as palatability, swallowability, dosing flexibility, pill burden, and dosing frequency, multiparticulate systems enable tailored drug delivery with improved compliance and therapeutic outcomes. This presentation will explore how taste masking, flexible formats, modified-release technologies, and combination designs collectively position multiparticulates as an innovative approach that combines convenience, flexibility, and patient-centric oral delivery.

Learning Objectives:

• • Identify five major patient-centric challenges addressed by multiparticulate formulations: taste masking, swallowability, dosing flexibility, pill burden, and dosing frequency.
• • Explain how multiparticulate platforms enable customized, age-appropriate, and easy-to-administer dosage forms.
• • Evaluate formulation and process strategies (e.g., coating, layering, encapsulation) that enhance palatability, modified release, and support combination therapies.
• • Review case studies demonstrating the utilization of multiparticulates in patient-centric therapies for pediatrics, geriatrics, and chronic disease management.

Lipid excipients offer significant in vivo performance benefits for oral drug delivery by improving solubility/bioavailability, enhancing absorption, and mitigating food effect. While lipids have found commercial success in soft gel capsules and liquid-filled hard capsules, there is growing interest in incorporating the benefits of lipid excipients into oral solid dosage forms, such as tablets.

This presentation will highlight emerging research and formulation strategies that expand the use of lipid excipients in oral tablet development.

Key topics will include:

• In vivo benefits of lipid excipients for solubility and permeability.
• Combining lipids with polymers to optimize oral tablet performance.
• Incorporating lipids into tablets via common processing techniques.
• Case studies showcasing lipid-enabled tablet formulations.

Precise storage conditions are critical to maintaining the quality and integrity of pharmaceutical products. Pharma storage must provide secure, cGMP-compliant solutions backed by advanced infrastructure, including redundant power and cooling systems, 24/7 monitoring, and multi-layered access control.

A full spectrum of storage environments—from ambient, refrigerated, and ICH stability to ultra-low and cryogenic—are needed to meet industry and custom requirements.

In this webinar, experts from Alcami will explore how integrated services such as materials management, logistics, and on-site support can ensure seamless handling from receipt to delivery, preserving product quality and meeting regulatory standards.

Attendees will gain insight on how to safeguard critical materials, mitigate risk, and navigate complex storage requirements with confidence across every stage of the development lifecycle.

Effective DNA clearance is essential in viral vector manufacturing to ensure product purity, regulatory compliance, and patient safety. As demand for AAV and LVV-based cell and gene therapies grows, biopharmaceuticals and CDMOs must adopt scalable, high-performing endonucleases. 

This study evaluated Roche’s EndoCleave endonuclease against commercial benchmarks using a transient transfection platform with suspension HEK293 cells. Two Proof-of-Concept studies assessed performance across key process parameters—enzyme concentration, incubation time, temperature, and salt conditions—representative of AAV and LVV production. 

EndoCleave consistently matched the performance of commercially available endonuclease in reducing host cell and plasmid DNA without impacting viral titers. Its activity remained robust under varying conditions, confirming suitability for both AAV and LVV workflows. 

These results suggest EndoCleave as a reliable, scalable solution for removing nucleic acid in GMP-ready vector manufacturing environments and could also be a potential cost-effective solution.

Multiparticulates like pellets, beads, and minitabs offer versatile solutions to address diverse patient-centric needs across pediatrics, geriatrics, and special populations. By overcoming key challenges such as palatability, swallowability, dosing flexibility, pill burden, and dosing frequency, multiparticulate systems enable tailored drug delivery with improved compliance and therapeutic outcomes. This presentation will explore how taste masking, flexible formats, modified-release technologies, and combination designs collectively position multiparticulates as an innovative approach that combines convenience, flexibility, and patient-centric oral delivery.

Learning Objectives:

• • Identify five major patient-centric challenges addressed by multiparticulate formulations: taste masking, swallowability, dosing flexibility, pill burden, and dosing frequency.
• • Explain how multiparticulate platforms enable customized, age-appropriate, and easy-to-administer dosage forms.
• • Evaluate formulation and process strategies (e.g., coating, layering, encapsulation) that enhance palatability, modified release, and support combination therapies.
• • Review case studies demonstrating the utilization of multiparticulates in patient-centric therapies for pediatrics, geriatrics, and chronic disease management.

Lipid excipients offer significant in vivo performance benefits for oral drug delivery by improving solubility/bioavailability, enhancing absorption, and mitigating food effect. While lipids have found commercial success in soft gel capsules and liquid-filled hard capsules, there is growing interest in incorporating the benefits of lipid excipients into oral solid dosage forms, such as tablets.

This presentation will highlight emerging research and formulation strategies that expand the use of lipid excipients in oral tablet development.

Key topics will include:

• In vivo benefits of lipid excipients for solubility and permeability.
• Combining lipids with polymers to optimize oral tablet performance.
• Incorporating lipids into tablets via common processing techniques.
• Case studies showcasing lipid-enabled tablet formulations.

Precise storage conditions are critical to maintaining the quality and integrity of pharmaceutical products. Pharma storage must provide secure, cGMP-compliant solutions backed by advanced infrastructure, including redundant power and cooling systems, 24/7 monitoring, and multi-layered access control.

A full spectrum of storage environments—from ambient, refrigerated, and ICH stability to ultra-low and cryogenic—are needed to meet industry and custom requirements.

In this webinar, experts from Alcami will explore how integrated services such as materials management, logistics, and on-site support can ensure seamless handling from receipt to delivery, preserving product quality and meeting regulatory standards.

Attendees will gain insight on how to safeguard critical materials, mitigate risk, and navigate complex storage requirements with confidence across every stage of the development lifecycle.

Effective DNA clearance is essential in viral vector manufacturing to ensure product purity, regulatory compliance, and patient safety. As demand for AAV and LVV-based cell and gene therapies grows, biopharmaceuticals and CDMOs must adopt scalable, high-performing endonucleases. 

This study evaluated Roche’s EndoCleave endonuclease against commercial benchmarks using a transient transfection platform with suspension HEK293 cells. Two Proof-of-Concept studies assessed performance across key process parameters—enzyme concentration, incubation time, temperature, and salt conditions—representative of AAV and LVV production. 

EndoCleave consistently matched the performance of commercially available endonuclease in reducing host cell and plasmid DNA without impacting viral titers. Its activity remained robust under varying conditions, confirming suitability for both AAV and LVV workflows. 

These results suggest EndoCleave as a reliable, scalable solution for removing nucleic acid in GMP-ready vector manufacturing environments and could also be a potential cost-effective solution.